GlassScriptPhysician profile
Dina Ioffe
NPI 1154856417
$6,505.58
in general payments reported to CMS, 2019-2025
10 companies · $3,802 in 2025
The $3,802 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.08 · 2023: $47.29 · 2024: $2,633 · 2025: $3,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,343 · Food and Beverage: $2,104 · Travel and Lodging: $990 · Education: $45.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,342.50 |
| Food and Beverage | $2,103.78 |
| Travel and Lodging | $989.71 |
| Education | $45.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,342.50 | 2025 | |
| Boston Scientific Corporation | $2,206.92 | 2024-2025 | Therasphere Y90 Glass Microspheres 10 Gbq, Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Astrazeneca Pharmaceuticals LP | $479.07 | 2024-2025 | Imfinzi, Enhertu |
| Eisai INC. | $183.00 | 2024-2025 | |
| Intera Oncology, INC | $107.25 | 2024 | Intera |
| Merck Sharp & Dohme LLC | $75.21 | 2023-2025 | Keytruda, Lynparza |
| Genentech USA, INC. | $46.49 | 2024 | |
| Sanofi-Aventis U.S. LLC | $27.48 | 2023 | |
| Daiichi Sankyo INC. | $24.08 | 2021 | |
| Caris Mpi, INC. | $13.58 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Ioffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.